ZINNAT Suspension (available as
cefuroxime axetil granules for oral
suspension, 125 mg/5ml, 70ml) will
be listed on the Pharmaceutical
Benefits Scheme as an unrestricted
General Benefit Item from 01
August 2012.
The listing follows a
recommendation by the
PBAC that Zinnat Suspension be
placed on the PBS on the basis of a
clinical need in the paediatric
population and acceptable cost
effectiveness.
Zinnat Suspension is indicated for
the treatment of mild to
moderately severe tonsillitis,
pharyngitis and acute bacterial
otitis media in paediatric patients 3
months to 12 years.The above article was sent to subscribers in Pharmacy Daily's issue from 31 Jul 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Jul 12
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
THE Pharmaceutical Society of Australia (PSA) has unveiled a comprehensive membership package designed to provide robust support for credentialed pharmacists throughout their professional journey.
MEDICAL research produces better outcomes when people with lived experience are involved in the process, according to Breast Cancer Network Australia (BCNA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.